This new US patent provides for a method of treating a tumor expressing a human papillomavirus (HPV) antigen through the administration of an effective amount of a composition comprised of an HPV antigen joined or fused to a stress protein. This patent provides additional patent exclusivity for HspE7, the company’s investigational therapeutic vaccine, and future HPV fusions through February 2019.
Gregory McKee, president and CEO of Nventa, said: “The issuance of this patent protecting the use of our HPV CoVal protein fusions to treat HPV-related diseases strengthens our intellectual property portfolio and, we believe, adds further value to our HspE7 program, which is currently in Phase I clinical development.”